Additional data in pregnant adults who are Virologically suppressed reinforce safety and tolerability profile of Biktarvy in broad range of people with HIV
Cellares will dedicate multiple Cell Shuttle and Cell Q systems with fully automated, high-throughput quality control for Bristol Myers Squibb’s exclusive use
Open a printable version of this pageEmail the URL of this page to a friend
NULIBRY is a first-in-class synthetic cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A
NexGard Spectra is a soft, flavourful monthly chew that kills fleas before they can lay eggs
The newly issued patent, US Patent No. 11,957,647, provides both expanded scope of protection as well as longer patent term
Breakthrough Therapy designation for pain associated with DPN granted by FDA
Interim analysis of an ongoing 156-week extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic and episodic migraine
Longest survival follow-up ever reported for immunotherapy treatment in this setting
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva
Subscribe To Our Newsletter & Stay Updated
